

CD



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/063,565	05/02/2002	Dan L. Eaton	P3230R1C001-168	2399
30313	7590	05/17/2004	EXAMINER	
KNOBBE, MARTENS, OLSON & BEAR, LLP			KAPUST, RACHEL B	
2040 MAIN STREET			ART UNIT	
FOURTEENTH FLOOR			PAPER NUMBER	
IRVINE, CA 92614			1647	

DATE MAILED: 05/17/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/063,565	EATON ET AL.	
	Examiner	Art Unit	
	Rachel B. Kapust	1647	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 12 September 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-13 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-13 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 02 May 2002 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Priority

According to the priority statement of September 12, 2002, the claimed subject matter defined in the instant application is supported by parent application serial nos. 10/006867, PCT/US00/23328, 09/380137, PCT/US99/12252, and 60/088734. Based on the information given by applicant and an inspection of the patent applications, the examiner has concluded that the subject matter defined in this application is not supported by the disclosures of 09/380137, PCT/US99/12252, and 60/088734 because no utility for the claimed polypeptide, PRO 1106, is disclosed in the earlier applications. Accordingly, the subject matter defined in claims 1-13 has an effective filing date of August 24, 2000.

Should the Applicant disagree with the examiner's factual determination above, it is incumbent upon the applicant to provide the serial number and specific page number(s) of any parent application filed prior to August 24, 2000 that specifically supports the particular claim limitation for each and every claim limitation in all the pending claims which applicant considers to have been in possession of and fully enabled prior to August 24, 2000.

Specification

The use of the trademarks KLENTAQ™ (p. 117), QIAQUICK™ (p. 119), SUPERFECT™ (p. 129), FUGENE™ (p. 129), and BACULOGOLD™ (p. 131) have been noted in this application. They should be capitalized wherever they appear and be accompanied by the generic terminology.

Although the use of trademarks is permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as trademarks.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 1-13 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific and substantial asserted utility or a well-established utility. Claims 1-13 are directed to polypeptides comprising SEQ ID NO: 58. The claimed polypeptides are not supported by either a specific and substantial asserted utility or a well-established utility.

A specific and substantial utility is one that is particular to the subject matter claimed and that identifies a "real world" use for the claimed invention. See *Brenner v. Manson*, 148 U.S.P.Q. 689 (1966):

The basic quid pro quo contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility. . . . [u]nless and until a process is refined and developed to this point-where specific benefit exists in currently available form-there is insufficient justification for permitting an applicant to engross what may prove to be a broad field.

Uses such as hybridization probes, chromosome and gene mapping, the generation of anti-sense RNA and DNA (p. 86), the preparation of PRO 1106 polypeptides, assaying for binding partners (p. 89), generating transgenic animals or knock-out animals (p. 90), using polypeptides as molecular weight markers (p. 92), and screening for agonists and antagonists of PRO 1106 (p. 95) are useful only in research to determine the function of the encoded protein itself. There is no "specific benefit in currently available form" to be derived from such studies. Tissue-specific expression such as that found on p. 142 (see DNA59609-1470) is not specific to the claimed polynucleotide. It does not depend on any characteristics of the nucleic acid molecule itself. Applicants teach that the PRO 1106 polypeptide or agonists or antagonists of PRO 1106 may be used in the preparation of medicaments, however the specification does not disclose any diseases or conditions known to be associated with the encoded protein. Further research would be required to identify a disease in which the encoded protein is involved. See *Brenner v. Manson*, noting that "a patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion." A patent is therefore not a license to

Art Unit: 1647

experiment. Further research would be required to determine how and if PRO 1106 is involved in any disease.

The invention also lacks a well-established utility. A well-established utility is a specific, substantial, and credible utility that is well known, immediately apparent, or implied by the specification's disclosure of the properties of a material. The specification fails to assert any activity for the polypeptide. Applicants have not asserted that PRO 1106 is a member of any protein family nor have Applicants asserted that PRO 1106 is homologous to any known proteins. The art is silent as to the activity of PRO 1106.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-6 and 10 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The limitation that the encoded protein comprises an "extracellular domain ... lacking its associated signal peptide" (claim 1, part (d), for example) is indefinite as a signal sequence is not generally considered to be part of an extracellular domain, as signal sequences are cleaved from said domains in the process of maturation.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-13 are also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific or substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

Claims 1-5 and 12-13 are rejected under 35 U.S.C. 112, first paragraph, because the specification, were it enabled for an isolated polypeptide having at least 80%, 85%, 90%, 95% or 99% amino acid sequence identity to the polypeptide of SEQ ID NO: 58, would still not reasonably provide enablement for a polypeptide not identical to at least the mature form of SEQ ID NO: 58. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

The factors considered when determining if the disclosure satisfies the enablement requirement and whether any necessary experimentation is undue include, but are not limited to: 1) nature of the invention, 2) state of the prior art, 3) relative skill of those in the art, 4) level of predictability in the art, 5) existence of working examples, 6) breadth of claims, 7) amount of direction or guidance by the inventor, and 8) quantity of experimentation needed to make or use the invention. *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).

The claims are drawn to a polypeptide having at least 80%, 85%, 90%, 95% or 99% amino acid sequence identity to the polypeptide of SEQ ID NO: 58, referred to as PRO1106. There is no functional limitation in the claims. Applicants have taught the polypeptide of SEQ ID NO: 58, as well as the putative signal sequence. However, there is no function known in the art to be associated with such a polypeptide, nor have Applicants provided any evidence of functions for the polypeptide.

The claims encompass an unreasonable number of inoperative polypeptides, which the skilled artisan would not know how to use. The specification provides no teachings as to the structural or related functional characteristics of this protein. There are no working examples of polypeptides less than 100% identical to the polypeptide comprising SEQ ID NO: 58. The skilled artisan would not know how to use non-identical polypeptides on the basis of teachings in the prior art or specification. The claims are broad because they do not require the claimed polypeptide to be identical to the disclosed sequence and because the claims have no functional limitation.

For these reasons, which include the complexity and unpredictability of the nature of the invention and art in terms of the diversity of transmembrane proteins, and lack of knowledge

about function(s) of encompassed polypeptides structurally related to SEQ ID NO: 58, the lack of direction or guidance for using polypeptides that are not identical to at least the mature form of SEQ ID NO: 58, and the breadth of the claims for structure without function, it would require undue experimentation to use the invention commensurate in scope with the claims.

Claims 1-5 and 12-13 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are drawn to polypeptides having at least 80%, 85%, 90%, 95% or 99% sequence identity with a particular disclosed sequence. The claims do not require that the encoded polypeptide possess any particular biological activity, nor any particular conserved structure, or other disclosed distinguishing feature. Thus, the claims are drawn to a genus of polypeptides that is defined only by sequence identity.

To provide adequate written description and evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof. In this case, the only factor present in the claims is a partial structure in the form of a recitation of percent identity. There is not even identification of any particular portion of the structure that must be conserved. As stated above, it is not even clear what region of the protein has the disclosed activity. Accordingly, in the absence of sufficient recitation of distinguishing identifying characteristics, the specification does not provide adequate written description of the claimed genus.

Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states “applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the ‘written description’ inquiry, whatever is now claimed.” (See page 1117.) The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See *Vas-Cath* at page 1116). As discussed above, the skilled artisan cannot envision the detailed chemical

structure of the encompassed genus of polypeptides, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The compound itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016.

One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481 at 1483. In *Fiddes*, claims directed to mammalian FGF's were found to be unpatentable due to lack of written description for that broad class. The specification provided only the bovine sequence.

Therefore, only isolated polypeptides comprising the amino acid sequence set forth in SEQ ID NO: 58 but not the full breadth of the claim meets the written description provision of 35 U.S.C. §112, first paragraph. Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. §112 is severable from its enablement provision (see page 1115).

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-4 are rejected under 35 U.S.C. 102(e) as being anticipated by U.S. Patent Application No. 6,573,095. Claims 1-4 are drawn to polypeptides that are at least 80%, 85%, 90%, or 95% identical to the amino acid sequence of SEQ ID NO: 58. The '095 patent teaches SEQ ID NO: 339 which is 97% identical to SEQ ID NO: 58 (see attached alignment). Thus, claims 1-4 are anticipated by the '095 patent.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 12-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 6,573,095. Claims 12-13 are drawn to chimeric polypeptides comprising a variant of SEQ ID NO: 58 and a heterologous polypeptide such as an epitope tag or an Fc region of an immunoglobulin. The '095 patent teaches a polypeptide that is 97% identical to SEQ ID NO: 58, but it does not teach a chimeric polypeptide comprising SEQ ID NO: 58. However, the '095 patent does teach chimeric polypeptides comprising Fc regions of immunoglobulins and other polypeptides. It would have been obvious to one of ordinary skill in the art to make similar chimeric polypeptides comprising an Fc region of an immunoglobulin and the polypeptide comprising SEQ ID NO: 58. One would have been motivated to do so because fusing the

Art Unit: 1647

polypeptide to an Fc region aided in the expression of the polypeptide, and similar results would be expected by expressing the polypeptide comprising SEQ ID NO: 58 in a similar manner.

Conclusion


NO CLAIMS ARE ALLOWED.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rachel B. Kapust whose telephone number is (571) 272-0886. The examiner can normally be reached on Mon-Fri 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz can be reached on (571) 272-0887. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

RBK
5/13/04


RACHEL B. KAPUST
PATENT EXAMINER

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 26, 2004, 14:22:47 ; Search time 22 Seconds
(without alignments)
1100.572 Million cell updates/sec

Title: US-10-063-565-58
Perfect score: 2423
Sequence: 1 MLCCLYVPVIGEAQTEFOY.....VSISYVVYENKILGLVQSR 469

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA:
1: /cgn2_6/prodata/2/iaa/5A COMB.pcp.*
2: /cgn2_6/prodata/2/iaa/5B COMB.pcp.*
3: /cgn2_6/prodata/2/iaa/6A COMB.pcp.*
4: /cgn2_6/prodata/2/iaa/6B COMB.pcp.*
5: /cgn2_6/prodata/2/iaa/6C COMB.pcp.*
6: /cgn2_6/prodata/2/iaa/backfiles1.pcp.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2362	97.5	469	3	US-09-188-930-339 Sequence 339, App
2	2362	97.5	469	4	US-09-312-283C-339 Sequence 339, App
3	1588	65.5	312	3	US-09-188-930-142 Sequence 142, App
4	1588	65.5	312	4	US-09-312-283C-142 Sequence 142, App
5	427.5	17.6	289	4	US-09-796-766-20 Sequence 20, App
6	418.5	17.3	433	4	US-09-796-766-18 Sequence 18, App
7	417	17.2	272	4	US-09-796-766-14 Sequence 14, App
8	415.5	17.1	436	4	US-09-796-766-21 Sequence 21, App
9	347.5	14.3	410	4	US-09-796-766-10 Sequence 10, App
10	314	13.0	298	4	US-09-434-354-49 Sequence 49, App
11	313	12.9	328	3	US-09-068-140A-15 Sequence 15, App
12	304	12.5	297	4	US-09-434-354-47 Sequence 47, App
13	302.5	12.5	320	2	US-08-933-750C-12 Sequence 12, App
14	302.5	12.5	320	3	US-09-234-613-12 Sequence 12, App
15	302.5	12.5	320	4	US-09-976-594-711 Sequence 711, App
16	302	12.5	298	3	US-08-961-871-10 Sequence 10, App
17	302	12.5	298	4	US-09-434-354-48 Sequence 48, App
18	299.5	12.4	289	3	US-09-068-140A-10 Sequence 10, App
19	286	11.8	335	4	US-09-482-273-118 Sequence 118, App
20	277	11.4	290	4	US-09-743-847-2 Sequence 2, App
21	272	11.2	252	4	US-09-796-766-4 Sequence 4, App
22	268	11.1	125	3	US-08-905-223-320 Sequence 320, App
23	265.5	11.0	291	4	US-09-501-558-2 Sequence 2, App
24	261	10.8	674	4	US-09-160-119-2 Sequence 2, App
25	245	10.1	309	4	US-10-001-051B-2 Sequence 2, App
26	242	10.0	309	1	US-08-518-878B-51 Sequence 51, App
27	242	10.0	309	2	US-08-807-861A-51 Sequence 51, App

28	242	10.0	309	2	US-08-470-868A-51	Sequence 51, Appl
29	242	10.0	309	3	US-09-210-681-51	Sequence 51, Appl
30	242	10.0	309	3	US-08-946-719A-51	Sequence 51, Appl
31	242	10.0	309	4	US-09-547-983-51	Sequence 51, Appl
32	242	10.0	309	4	US-09-743-847-4	Sequence 4, Appl
33	239.5	9.9	299	1	US-08-518-878B-56	Sequence 56, Appl
34	239.5	9.9	299	2	US-08-470-868A-56	Sequence 56, Appl
35	237.5	9.8	351	2	US-08-933-750C-19	Sequence 19, Appl
36	237.5	9.8	351	3	US-09-234-613-19	Sequence 19, Appl
37	236	9.7	312	4	US-09-142-565-2	Sequence 2, Appl
38	236	9.7	312	4	US-09-808-457-2	Sequence 2, Appl
39	236	9.7	312	4	US-09-423-410-4	Sequence 4, Appl
40	234	9.7	447	4	US-09-160-119-4	Sequence 4, Appl
41	231	9.5	432	2	US-08-937-466-4	Sequence 4, Appl
42	231	9.5	432	2	US-09-172-528-4	Sequence 4, Appl
43	231	9.5	432	3	US-09-318-199-4	Sequence 4, Appl
44	231	9.5	432	3	US-09-503-579-4	Sequence 4, Appl
45	228	9.4	308	2	US-08-937-466-2	Sequence 2, Appl

ALIGNMENTS

Patent No. 6150502
GENERAL INFORMATION:
APPLICANT: Watson, James D.
APPLICANT: Strachan, Lorna
APPLICANT: Sleeman, Matthew
APPLICANT: Onrust, Rene
APPLICANT: Murison, James Greg
TITLE OF INVENTION: Compositions Isolated From Skin Cells
TITLE OF INVENTION: and Methods For Their Use
FILE REFERENCE: 11000.1011c1
CURRENT APPLICATION NUMBER: US/09/188,930A
CURRENT FILING DATE: 1998-11-09
NUMBER OF SEQ ID NOS: 348
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 339
LENGTH: 469
TYPE: PRT
ORGANISM: Mouse
US-09-188-930-339

Query Match	97.5%	Score	2362	DB 3	Length	469			
Best Local Similarity	97.2%	Pred. No.	1.3e-228						
Matches	456	Conservative	6	Mismatches	7	Indels	0	Gaps	0
QY	1	MLCCLYVPVIGEAQTEFOYFESKGLPAELKSIKLSVFIPOEFSTYQWKQKIVOAGD	60						
Db	1	MLCCLYVPVIGAAQTEFOYFESKGLPAELKSIKLSVFIPOEFSTYQWKQKIVOAGD	60						
QY	61	KOLDGOLDPEEFVHYLODHEKRLVFKLTDKKNDRIDAQETMQSLRDLGVKISEQOAE	120						
Db	61	KOLDGOLDPEEFVHYLODHEKRLVFKSLDKKNDRIDAQETMQSLRDLGVKISEQOAE	120						
QY	121	KILKSMKNGTMTIDWNEWRDYHLLHPVENIPILLYKXHSITFDVGENLTPDFTVEE	180						
Db	121	KILKSMKNGTMTIDWNEWRDYHLLHPVENIPILLYKXHSITFDVGENLTPDFTVEE	180						
QY	181	ROTGMWRHLVAGGGAGAVSRCTAPDLRLKVLQMVHASRNNMGIVGFTQMIREGGAR	240						
Db	181	ROTGMWRHLVAGGGAGAVSRCTAPDLRLKVLQMVHASRNNMCIYVGGFTQMIREGGAK	240						
QY	241	SLWRGNGINVLKAPESAIKFMAVYQIKELVGSDOETLRIHERLVAGSLAGIAQAQSIYIP	300						
Db	241	SLWRGNGINVLKAPESAIKFMAVYQMKELVGSDOETLRIHERLVAGSLAGIAQAQSIYIP	300						
QY	301	MEVLKTRMALRTGYSGMLDCARRILAREGVAAFYKGVPMGLIIPVAGIDLAVYETL	360						
Db	301	MEVLKTRMALRTGYSGMLDCARRILAREGVAAFYKGVPMGLIIPVAGIDLAVYETL	360						

QY 361 KNAWLQHYAVNSADPGVFFVLLACGTMSSCTCGQLASVPLALVTRMQAASIEGAPVETMS 420
Db 361 KNTWLQRYAVNSADPGVFFVLLACGTTISCTCGQLASVPLALVTRMQAASIEGAPVETMS 420
QY 421 SLFKHILRTGAFGLYRGGLAPNFMKVIPIAVSISVYVYENLKITLGVQSR 469
Db 421 SLFKQILRTGAFGLYRGGLAPNFMKVIPIAVSISVYVYENLKITLGVQSR 469

RESULT 2

US-09-312-283C-339

; Sequence 339, Application US/09312283C

; Patent No. 6573095

; GENERAL INFORMATION:

; APPLICANT: Watson, James D.

; APPLICANT: Strachan, Lorna

; APPLICANT: Sleeman, Matthew

; APPLICANT: Onrust, Rene

; APPLICANT: Murison, James G.

; APPLICANT: Kumble, Krishanand D.

; TITLE OF INVENTION: Compositions Isolated from Skin Cells

; TITLE OF INVENTION: and Methods for Their Use

; FILE REFERENCE: 11000.1011C2

; CURRENT APPLICATION NUMBER: US/09/312,283C

; CURRENT FILING DATE: 1999-05-14

; NUMBER OF SEQ ID NOS: 425

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 339

; LENGTH: 469

; TYPE: PRT

; ORGANISM: Mouse

US-09-312-283C-339

Query Match 97.5%; Score 2362; DB 4; Length 469;
Best Local Similarity 97.2%; Pred. No. 1.3e-228;
Matches 456; Conservative 6; Mismatches 7; Indels 0; Gaps 0;

QY 1 MLCLCLYVPVIGEAGTEFOYFESKGLPAELKSIFKLSVFIPOSFSTYROWKQKIVQAGD 60

Db 1 MLCLCLYVPVIGEAGTEFOYFESKGLPAELKSIFKLSVFIPOSFSTYROWKQKIVQAGD 60

QY 61 KDLGGQLDFFEFVHYLQDHEKRLVFKILDKNDGRIDAQEIIMQSLRDLGVKISEQAAE 120

Db 61 KDLGGQLDFFEFVHYLQDHEKRLVFKILDKNDGRIDAQEIIMQSLRDLGVKISEQAAE 120

QY 121 KILKSMKDKNGTMTIDWNEWRDYHLLHPVENIPEIILYWKHSTIFDVGENLTVPDEFTVEE 180

Db 121 KILKSMKDKNGTMTIDWNEWRDYHLLHPVENIPEIILYWKHSTIFDVGENLTVPDEFTVEE 180

QY 181 ROTGMMWRHLVAGGAGAVSRTCTAPLDRLKVLMOVHASRNNMGIVGGFTQMIREGGAR 240

Db 181 ROTGMMWRHLVAGGAGAVSRTCTAPLDRLKVLMOVHASRNNMGIVGGFTQMIREGGAR 240

QY 241 SLWNGNGINVLKIAPESAIKFMAYEQIKRLVGSQDQETLRHERLVAGSLAGAIQSSIYP 300

Db 241 SLWNGNGINVLKIAPESAIKFMAYEQIKRLVGSQDQETLRHERLVAGSLAGAIQSSIYP 300

QY 301 MEVLKTRMALRKTGOYSGMLDCARRILAREGVAAYFKYGVNMLGIIPYAGIDLAVYETL 360

Db 301 MEVLKTRMALRKTGOYSGMLDCARRILAREGVAAYFKYGVNMLGIIPYAGIDLAVYETL 360

QY 361 KNAWLQHYAVNSADPGVFFVLLACGTMSSCTCGQLASVPLALVTRMQAASIEGAPVETMS 420

Db 361 KNTWLQRYAVNSADPGVFFVLLACGTTISCTCGQLASVPLALVTRMQAASIEGAPVETMS 420

QY 421 SLFKHILRTGAFGLYRGGLAPNFMKVIPIAVSISVYVYENLKITLGVQSR 469

Db 421 SLFKQILRTGAFGLYRGGLAPNFMKVIPIAVSISVYVYENLKITLGVQSR 469

RESULT 3

US-09-188-930-142

; Sequence 142, Application US/09188930A

; Patent No. 6150502

; GENERAL INFORMATION:

; APPLICANT: Watson, James D.

; APPLICANT: Strachan, Lorna

; APPLICANT: Sleeman, Matthew

; APPLICANT: Onrust, Rene

; APPLICANT: Murison, James Greg

; TITLE OF INVENTION: Compositions Isolated from Skin Cells

; TITLE OF INVENTION: and Methods for Their Use

; FILE REFERENCE: 11000.1011C1

; CURRENT APPLICATION NUMBER: US/09/188,930A

; CURRENT FILING DATE: 1998-11-09

; NUMBER OF SEQ ID NOS: 348

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 142

; LENGTH: 312

; TYPE: PRT

; ORGANISM: mouse

US-09-188-930-142

Query Match 65.5%; Score 1588; DB 3; Length 312;
Best Local Similarity 97.8%; Pred. No. 4.2e-151;
Matches 305; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1 MLCLCLYVPVIGEAGTEFOYFESKGLPAELKSIFKLSVFIPOSFSTYROWKQKIVQAGD 60

Db 1 MLCLCLYVPVIGEAGTEFOYFESKGLPAELKSIFKLSVFIPOSFSTYROWKQKIVQAGD 60

QY 61 KDLGGQLDFFEFVHYLQDHEKRLVFKILDKNDGRIDAQEIIMQSLRDLGVKISEQAAE 120

Db 61 KDLGGQLDFFEFVHYLQDHEKRLVFKILDKNDGRIDAQEIIMQSLRDLGVKISEQAAE 120

QY 121 KILKSMKDKNGTMTIDWNEWRDYHLLHPVENIPEIILYWKHSTIFDVGENLTVPDEFTVEE 180

Db 121 KILKSMKDKNGTMTIDWNEWRDYHLLHPVENIPEIILYWKHSTIFDVGENLTVPDEFTVEE 180

QY 181 ROTGMMWRHLVAGGAGAVSRTCTAPLDRLKVLMOVHASRNNMGIVGGFTQMIREGGAR 240

Db 181 ROTGMMWRHLVAGGAGAVSRTCTAPLDRLKVLMOVHASRNNMGIVGGFTQMIREGGAR 240

QY 241 SLWNGNGINVLKIAPESAIKFMAYEQIKRLVGSQDQETLRHERLVAGSLAGAIQSSIYP 300

Db 241 SLWNGNGINVLKIAPESAIKFMAYEQIKRLVGSQDQETLRHERLVAGSLAGAIQSSIYP 300

QY 301 MEVLKTRMALRKTGOYSGMLDCARRILAREGVAAYFKYGVNMLGIIPYAGIDLAVYETL 312

Db 301 MEVLKTRMALRKTGOYSGMLDCARRILAREGVAAYFKYGVNMLGIIPYAGIDLAVYETL 312

RESULT 4

US-09-312-283C-142

; Sequence 142, Application US/09312283C

; Patent No. 6573095

; GENERAL INFORMATION:

; APPLICANT: Watson, James D.

; APPLICANT: Strachan, Lorna

; APPLICANT: Sleeman, Matthew

; APPLICANT: Onrust, Rene

; APPLICANT: Murison, James G.

; APPLICANT: Kumble, Krishanand D.

; TITLE OF INVENTION: Compositions Isolated from Skin Cells

; TITLE OF INVENTION: and Methods for Their Use

; FILE REFERENCE: 11000.1011C2

; CURRENT APPLICATION NUMBER: US/09/312,283C

; CURRENT FILING DATE: 1999-05-14

; NUMBER OF SEQ ID NOS: 425

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 142

; LENGTH: 312

; TYPE: PRT

; ORGANISM: Mouse

US-09-312-283C-142